The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies

Neurology

Volumn 61, Issue 7, 2003, Pages 944-949

  Murman, Daniel L ^a   Kuo, Sherry B ^a   Powell, Michelle C ^a   Colenda, Christopher C ^b  

^a East Lansing   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DEMENTIA; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS OF COVARIANCE; PARKINSONISM; PRIORITY JOURNAL;

EID: 0141959166     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.61.7.944     Document Type: Article

References (27)

1. Mitchell SL. Extrapyramidal features in Alzheimer's disease. Age Ageing 1999;28:401-409.
2. McKeith LG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
3. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology 1994;44:2300-2307.
4. Clark CM, Ewbank D, Lerner A, et al. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease Neurology 1997;49:70-75.
5. Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998;51:351-357.
6. Ballard C, Shaw F, Lowery K, McKeith I, Kenny R. The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:77-103.
7. Mitchell SL, Rockwood K. The association between parkinsonism, Alzheimer's disease, and mortality: a comprehensive approach. J Am Geriatr Soc 2000;48:422-425.
8. Murman D, Chen Q, Colucci P, Colenda C, Gelb D, Liang J. Comparison of healthcare utilization and direct costs in three degenerative dementias. Am J Geriatr Psychiatry 2002;10:328-336.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
10. Richards M, Marder K, Bell K, Dooneief G, Mayeux R, Stern Y. Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol 1991;48:1147-1149.
11. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992;40:922-935.
12. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130-137.
13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
14. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002;59:1721-1729.
15. Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 1995;58:228-236.
16. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
17. Bureau of Labor Statistics US Department of Labor. Consumer Price Indexes. Available at: http://www.bls.gov/cpi/. Accessed January 28, 2003.
18. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-295.
19. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
20. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord 2002;13:67-73.
21. Swanberg MM, Cummings JL. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Saf 2002;25:511-523.
22. Fillit H, Geldmacher DS, Welter RT, Maslow K, Fraser M. Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias. J Am Geriatr Soc 2002;50:1871-1878.
23. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955.
24. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107-115.
25. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-794.
26. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000;17:363-384.
27. Corder LS, Woodbury MA, Manton KG. Proxy response patterns among the aged: effects on estimates of health status and medical care utilization from the 1982-1984 long-term care surveys. J Clin Epidemiol 1996;49:173-182.